Breakthrough in Thermal Gradient's fast PCR technology for molecular diagnostics

NewsGuard 100/100 Score

Thermal Gradient, a Rochester, NY biotech company, announces a breakthrough in its fast PCR technology for molecular diagnostics.  PCR (polymerase chain reaction) is the preferred critical step in virtually all forms of DNA testing.

The company's latest generation of amplification devices has successfully developed and demonstrated the performance of PCR at speeds many times faster than conventional methods, achieving 8.5 decades of amplification (greater than 300 million times) in just eight minutes.  For the first time, these simple devices are being made from low cost materials suitable for high volume manufacturing processes.  The company believes that it now has the best platform for molecular testing that addresses ease of use, fast performance, and low cost operation.

The current generation of devices, developed under an NIH grant, are aimed at rapid point-of-care HIV testing in low resource settings.  As such, they need to be easy to use, appropriate for field deployment, work very fast, and be produced in very large quantities at very low unit cost.  By demonstrating that high performance can be achieved in devices fabricated with materials suitable for mass production processes the company has taken a major step toward those goals. With this early success, the company has committed to its first mass producible injection molded design.  Testing of these units is expected early in January of 2011.

These amplification devices are used in a cartridge that is already in development.  This cartridge will be a single use, disposable unit that integrates sample preparation from whole blood, PCR amplification, and real-time detection.  The instrument that will process these cartridges is also under development.

SOURCE Thermal Gradient Inc

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New tARC-seq method enhances precision in tracking SARS-CoV-2 mutations